More Accuracy, Less Speed? ASCO 2026 Data Further Support Targeted Therapy in Early-Stage NSCLC

More Accuracy, Less Speed? ASCO 2026 Data Further Support Targeted Therapy in Early-Stage NSCLC

Data presented at ASCO 2026 further underscore the importance of identifying which patients with early-stage NSCLC are eligible for targeted therapies. Jamie E. Chaft, MD, discusses results from the LIBRETTO, CROWN, and EA5142 trials with LungCancerRx hosts Aakash Desai, MD, MPH, Eric K. Singhi, MD, and Fawzi F. Abu Rous, MD.

What Do ASCO 2026 Data on NSCLC Co-mutations Mean for Practice?

Ferdinandos Skoulidis, MD, PhD, discusses data on KRAS- mutated NSCLC from ASCO 2026 with Aakash Desai, MD, MPH, Fawzi F. Abu Rous, MD, and Eric K. Singhi, MD.

Neoadjuvant Therapy for Early-Stage Lung Cancer: Where Do Things Stand, and What’s Next?

Given recent advances, where do things stand for neoadjuvant therapy in patients with NSCLC? The panel discusses current considerations and what important questions may soon be answered. Patrick Forde MBBCh, PhD, a thoracic medical oncologist at Johns Hopkins University in Baltimore, Maryland, and professor of immuno-oncology at Trinity College Dublin discusses current multidisciplinary approaches to perioperative care in NSCLC with Eric K. Singhi, MD, a thoracic oncologist in Houston, and Aakash Desai, MD, MPH, an assistant professor at the University of Alabama at Birmingham’s O’Neal Cancer Center.

Lung Cancer Myths: Separating Fact From Fiction

From screening to treatment, myths and misperceptions about lung cancer present challenges for physicians and patients. From setting the record straight on surgical approaches to setting higher expectations for treatment outcomes, the LungCancerRx panel tackles key questions currently faced in practice.

“Just Doesn’t Make Sense”: What’s Missing When It Comes to Diagnosing Lung Cancer

Despite notable recent advances in lung cancer treatment, early diagnosis remains a challenge. From problems with screening criteria to changes in disease demographics, the LungCancerRx panel explains why the only solution is “education, education, education.”